Abstract
Human NIN1/RPN12 binding protein 1 homolog (NOB1), an RNA binding protein, is expressed ubiquitously in normal tissues such as the lung, liver, and spleen. Its core physiological function is to regulate protease activities and participate in maintaining RNA metabolism and stability. NOB1 is overexpressed in a variety of cancers, including pancreatic cancer, non-small cell lung cancer, ovarian cancer, prostate carcinoma, osteosarcoma, papillary thyroid carcinoma, colorectal cancer, and glioma. Although existing data indicate that NOB1 overexpression is associated with cancer growth, invasion, and poor prognosis, the molecular mechanisms behind these effects and its exact roles remain unclear. Several studies have confirmed that NOB1 is clinically relevant in different cancers, and further research at the molecular level will help evaluate the role of NOB1 in tumors. NOB1 has become an attractive target in anticancer therapy because it is overexpressed in many cancers and mediates different stages of tumor development. Elucidating the role of NOB1 in different signaling pathways as a potential cancer treatment will provide new ideas for existing cancer treatment methods. This review summarizes the research progress made into NOB1 in cancer in the past decade; this information provides valuable clues and theoretical guidance for future anticancer therapy by targeting NOB1.
Keywords: Cancer, NIN1/RPN12 binding protein 1 homolog (NOB1), signaling pathway, targeted therapy, RNA metabolism, anticancer therapy.
Graphical Abstract
[1]
Tone Y, Tanahashi N, Tanaka K, Fujimuro M, Yokosawa H, Toh-e A. Nob1p, a new essential protein, associates with the 26s proteasome of growing saccharomyces cerevisiae cells. Gene 2000; 243(1-2): 37-45.
[2]
Zhang Y, Ni J, Zhou G, et al. Cloning, expression and characterization of the human nob1 gene. Mol Biol Rep 2005; 32(3): 185-9.
[3]
Han Y, Hong L, Qiu J, et al. Preparation and characterization of a novel monoclonal antibody specific to human nob1 protein. Hybridoma (Larchmt) 2008; 27(3): 187-90.
[4]
Tone Y, Toh EA. Nob1p is required for biogenesis of the 26s proteasome and degraded upon its maturation in saccharomyces cerevisiae. Genes Dev 2002; 16(24): 3142-57.
[5]
Zhou GJ, Zhang Y, Wang J, et al. Cloning and characterization of a novel human rna binding protein gene pno1 DNA sequence: the journal of DNA sequencing and mapping 2004; 15(3): 219-24.
[6]
Granneman S, Petfalski E, Swiatkowska A, Tollervey D. Cracking pre-40s ribosomal subunit structure by systematic analyses of rna-protein cross-linking. EMBO J 2010; 29(12): 2026-36.
[7]
Han Y, Hong L, Zhong C, et al. Identification of new altered genes in rat cochleae with noise-induced hearing loss. Gene 2012; 499(2): 318-22.
[8]
Han Y, Hong L, Chen Y, et al. Up-regulation of nob1 in the rat auditory system with noise-induced hearing loss. Neurosci Lett 2011; 491(1): 79-82.
[9]
Liu K, Chen HL, Gu MM, You QS. Relationship between nob1 expression and prognosis of resected non-small cell lung cancer. Int J Biol Markers 2015; 30(1): e43-8.
[10]
Lin Y, Peng S, Yu H, Teng H, Cui M. Rnai-mediated downregulation of nob1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Med Oncol 2012; 29(1): 311-7.
[11]
Chen J, Wang J, Cui X, et al. Positive nin one binding protein expression predicts poor outcome in prostate cancer. Mol Med Rep 2015; 11(4): 2671-6.
[12]
Luo L, Wang Y, Yin Y, Ge J, Lu X. Effects of nob1 on the pathogenesis of osteosarcoma and its expression on the chemosensitivity to cisplatin. Oncol Lett 2018; 15(3): 3548-51.
[13]
Lin S, Meng W, Zhang W, et al. Expression of the nob1 gene and its clinical significance in papillary thyroid carcinoma. J Int Med Res 2013; 41(3): 568-72.
[14]
He XW, Feng T, Yin QL, Jian YW, Liu T. Nob1 is essential for the survival of rko colorectal cancer cells. World J Gastroenterol 2015; 21(3): 868-77.
[15]
Wang H, Li P, Zhao B. Knockdown of nob1 expression by rnai inhibits cellular proliferation and migration in human gliomas. Gene 2013; 528(2): 146-53.
[16]
Fatica A, Tollervey D, Dlakic M. Pin domain of nob1p is required for d-site cleavage in 20s pre-rrna. RNA 2004; 10(11): 1698-701.
[17]
Pertschy B, Schneider C, Gnadig M, Schafer T, Tollervey D, Hurt E. Rna helicase prp43 and its co-factor pfa1 promote 20 to 18 s rrna processing catalyzed by the endonuclease nob1. J Biol Chem 2009; 284(50): 35079-91.
[18]
Senissar M, Manav MC, Brodersen DE. Structural conservation of the pin domain active site across all domains of life. Protein Sci 2017; 26(8): 1474-92.
[19]
Matelska D, Steczkiewicz K, Ginalski K. Comprehensive classification of the pin domain-like superfamily. Nucleic Acids Res 2017; 45(12): 6995-7020.
[20]
Doerks T, Copley RR, Schultz J, Ponting CP, Bork P. Systematic identification of novel protein domain families associated with nuclear functions. Genome Res 2002; 12(1): 47-56.
[21]
Lamanna AC, Karbstein K. Nob1 binds the single-stranded cleavage site d at the 3′-end of 18s rrna with its pin domain. Proc Natl Acad Sci USA 2009; 106(34): 14259-64.
[22]
Fatica A, Oeffinger M, Dlakic M, Tollervey D. Nob1p is required for cleavage of the 3′ end of 18s rrna. Mol Cell Biol 2003; 23(5): 1798-807.
[23]
Lamanna AC, Karbstein K. An rna conformational switch regulates pre-18s rrna cleavage. J Mol Biol 2011; 405(1): 3-17.
[24]
Montellese C, Montel-Lehry N, Henras AK, Kutay U, Gleizes PE, O’Donohue MF. Poly(a)-specific ribonuclease is a nuclear ribosome biogenesis factor involved in human 18s rrna maturation. Nucleic Acids Res 2017; 45(11): 6822-36.
[25]
Veith T, Martin R, Wurm JP, et al. Structural and functional analysis of the archaeal endonuclease nob1. Nucleic Acids Res 2012; 40(7): 3259-74.
[26]
Guex N, Peitsch MC, Schwede T. Automated comparative protein structure modeling with swiss-model and swiss-pdbviewer: A historical perspective. Electrophoresis 2009; 30(S1): S162-73.
[27]
Turowski TW, Lebaron S, Zhang E, et al. Rio1 mediates atp-dependent final maturation of 40s ribosomal subunits. Nucleic Acids Res 2014; 42(19): 12189-99.
[28]
Missbach S, Weis BL, Martin R, Simm S, Bohnsack MT, Schleiff E. 40s ribosome biogenesis co-factors are essential for gametophyte and embryo development. PLoS One 2013; 8(1)e54084
[30]
Fujimuro M, Tanaka K, Yokosawa H, Toh-e A. Son1p is a component of the 26s proteasome of the yeast saccharomyces cerevisiae. FEBS Lett 1998; 423(2): 149-54.
[31]
Hellmich UA, Weis BL, Lioutikov A, et al. Essential ribosome assembly factor fap7 regulates a hierarchy of rna-protein interactions during small ribosomal subunit biogenesis. Proc Natl Acad Sci USA 2013; 110(38): 15253-8.
[32]
Campbell MG, Karbstein K. Protein-protein interactions within late pre-40s ribosomes. PLoS One 2011; 6(1)e16194
[33]
Lebaron S, Schneider C, van Nues RW, et al. Proofreading of pre-40s ribosome maturation by a translation initiation factor and 60s subunits. Nat Struct Mol Biol 2012; 19(8): 744-53.
[34]
Zemp I, Wandrey F, Rao S, et al. Ck1delta and ck1epsilon are components of human 40s subunit precursors required for cytoplasmic 40s maturation. J Cell Sci 2014; 127(Pt 6): 1242-53.
[35]
Heuer A, Thomson E, Schmidt C, et al. Cryo-em structure of a late pre-40s ribosomal subunit from saccharomyces cerevisiae. eLife 2017; 6e30189
[36]
Veith T, Wurm JP, Duchardt-Ferner E, et al. Backbone and side chain nmr resonance assignments for an archaeal homolog of the endonuclease nob1 involved in ribosome biogenesis. Biomol NMR Assign 2012; 6(1): 47-50.
[37]
Kala S, Mehta V, Yip CW, et al. The interaction of a trypanosoma brucei kh-domain protein with a ribonuclease is implicated in ribosome processing. Mol Biochem Parasitol 2017; 211: 94-103.
[38]
Wang X, Wu T, Hu Y, et al. Pno1 tissue-specific expression and its functions related to the immune responses and proteasome activities. PLoS One 2012; 7(9)e46093
[39]
Landvogt L, Ruland JA, Montellese C, Siebrasse JP, Kutay U, Kubitscheck U. Observing and tracking single small ribosomal subunits in vivo. Methods (San Diego, Calif) 2019; 153: 63-70.
[40]
Ameismeier M, Cheng J, Berninghausen O, Beckmann R. Visualizing late states of human 40s ribosomal subunit maturation. Nature 2018; 558(7709): 249-53.
[41]
Woolls HA, Lamanna AC, Karbstein K. Roles of dim2 in ribosome assembly. J Biol Chem 2011; 286(4): 2578-86.
[42]
Che JP, Li W, Yan Y, et al. Expression and clinical significance of the nin one binding protein and p38 mapk in prostate carcinoma. International journal of clinical and experimental pathology 2013; 6(11): 2300-11.
[43]
Huang WY, Chen DH, Ning L, Wang LW. Sirna mediated silencing of nin1/rpn12 binding protein 1 homolog inhibits proliferation and growth of breast cancer cells. Asian Pacific journal of cancer prevention. APJCP 2012; 13(5): 1823-7.
[44]
Jia JW, Liu AQ, Wang Y, Zhao F, Jiao LL, Tan J. Evaluation of nin/rpn12 binding protein inhibits proliferation and growth in human renal cancer cells. Tumour Biol 2015; 36(3): 1803-10.
[45]
Zhou WP, Liu X, Yang Y, Liu YF. Expression mechanism and clinical significance of nob1 in gastric cancer tissue and adjacent normal tissue. Journal of biological regulators and homeostatic agents 2015; 29(2): 423-30.
[46]
Wang J, Cao L, Wu J, Wang Q. Long non-coding rna snhg1 regulates nob1 expression by sponging mir-326 and promotes tumorigenesis in osteosarcoma. Int J Oncol 2018; 52(1): 77-88.
[47]
Deng Y, Li Y, Fang Q, Luo H, Zhu G. Microrna-744 is downregulated in glioblastoma and inhibits the aggressive behaviors by directly targeting nob1. Am J of Cancer Res 2018; 8(11): 2238-53.
[48]
Sun J, Fan Z, Lu S, Yang J, Hao T, Huo Q. Mir-192 suppresses the tumorigenicity of prostate cancer cells by targeting and inhibiting nin one binding protein. Int J Mol Med 2016; 37(2): 485-92.
[49]
Kong R, Liu W, Guo Y, et al. Inhibition of nob1 by microrna-330-5p overexpression represses cell growth of non-small cell lung cancer. Oncol Rep 2017; 38(4): 2572-80.
[50]
Lin Y, Jin Y, Xu T, Zhou S, Cui M. Microrna-215 targets nob1 and inhibits growth and invasion of epithelial ovarian cancer. Am J of Transl Res 2017; 9(2): 466-77.
[51]
Lin Y, Xu T, Zhou S, Cui M. Microrna-363 inhibits ovarian cancer progression by inhibiting nob1. Oncotarget 2017; 8(60): 101649-58.
[52]
Dai H, Hou K, Cai Z, Zhou Q, Zhu S. Low-level mir-646 in colorectal cancer inhibits cell proliferation and migration by targeting nob1 expression. Oncol Lett 2017; 14(6): 6708-14.
[53]
Zhou J, Xu T, Yan Y, et al. Microrna-326 functions as a tumor suppressor in glioma by targeting the nin one binding protein (nob1). PLoS One 2013; 8(7)e68469
[54]
Wu L, Hui H, Wang LJ, Wang H, Liu QF, Han SX. Microrna-326 functions as a tumor suppressor in colorectal cancer by targeting the nin one binding protein. Oncol Rep 2015; 33(5): 2309-18.
[55]
Huang P, Xi J, Liu S. Mir-139-3p induces cell apoptosis and inhibits metastasis of cervical cancer by targeting nob1. Biomed Pharmacother 2016; 83: 850-6.
[56]
Li W, Liu M, Feng Y, et al. Downregulated mir-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (nob1). Br J Cancer 2014; 111(6): 1188-200.
[57]
Liu K, Gu MM, Chen HL, You QS. Nob1 in non-small-cell lung cancer: Expression profile and clinical significance. Pathol Oncol Res 2014; 20(2): 461-6.
[58]
Liu K, Chen HL, Gu MM, You QS. Nob1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer. J Chemother 2016; 28(3): 225-9.
[59]
Liu K, Chen HL, Gu MM, You QS. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer. International journal of clinical and experimental pathology 2015; 8(12): 16081-8.
[60]
Liu K, Chen HL, Wang S, et al. High expression of riok2 and nob1 predict human non-small cell lung cancer outcomes. Sci Rep 2016; 6: 28666.
[61]
Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (cdk1) but not cdk4/6 or cdk2 is selectively lethal to myc-dependent human breast cancer cells. BMC Cancer 2014; 14: 32.
[62]
Chohan TA, Qian H, Pan Y, Chen JZ. Cyclin-dependent kinase-2 as a target for cancer therapy: Progress in the development of cdk2 inhibitors as anti-cancer agents. Curr Med Chem 2015; 22(2): 237-63.
[63]
de Avila MB, Xavier MM, Pintro VO, de Azevedo WF Jr. Supervised machine learning techniques to predict binding affinity. A study for cyclin-dependent kinase 2. Biochemical and biophysical research communications 2017; 494(1-2): 305-10.
[64]
Levin NMB, Pintro VO, de Avila MB, de Mattos BB, De Azevedo WF Jr. Understanding the structural basis for inhibition of cyclin-dependent kinases. New pieces in the molecular puzzle. Curr Drug Targets 2017; 18(9): 1104-11.
[65]
Levin NMB, Pintro VO, Bitencourt-Ferreira G, de Mattos BB, de Castro Silverio A, de Azevedo WF Jr. Development of cdk-targeted scoring functions for prediction of binding affinity. Biophys Chem 2018; 235: 1-8.
[66]
Volkart PA, Bitencourt-Ferreira G, Souto AA, de Azevedo WF. Cyclin-dependent kinase 2 in cellular senescence and cancer. A structural and functional review. Curr Drug Targets 2018.
[http://dx.doi.org/10.2174/1389450120666181204165344]
[http://dx.doi.org/10.2174/1389450120666181204165344]
[67]
de Azevedo WF. Opinion paper: Targeting multiple cyclin-dependent kinases (cdks): A new strategy for molecular docking studies. Curr Drug Targets 2016; 17(1): 2.
[68]
Li Y, Ma C, Qian M, Wen Z, Jing H, Qian D. Downregulation of nob1 suppresses the proliferation and tumor growth of non-small cell lung cancer in vitro and in vivo. Oncol Rep 2014; 31(3): 1271-6.
[69]
Huang W, Zhong W, Xu J, et al. Lentivirus-mediated gene silencing of nob1 suppresses non-small cell lung cancer cell proliferation. Oncol Rep 2015; 34(3): 1510-6.
[70]
Liu K, Chen H, You Q, et al. Mir145 inhibits human nonsmall-cell lung cancer growth by dual-targeting riok2 and nob1. Int J Oncol 2018; 53(1): 257-65.
[71]
Lin Y, Xu T, Teng H, Cui M. Anticancer activity of nob1-targeted shrna combination with trail in epithelial ovarian cancer cells. International journal of clinical and experimental pathology 2015; 8(9): 10061-71.
[72]
Liu G, Shen D, Jiao L, Sun Y. Nin one binding protein expression as a prognostic marker in prostate carcinoma. Clin Transl Oncol 2014; 16(9): 843-7.
[73]
Chen B, Liu J, Wu D, et al. Gene silencing of nob1 by lentivirus suppresses growth and migration of human osteosarcoma cells. Mol Med Rep 2014; 9(6): 2173-9.
[74]
Liu J, Dong BF, Wang PS, et al. Silencing nob1 enhances doxorubicin antitumor activity of the papillary thyroid carcinoma in vitro and in vivo. Oncol Rep 2015; 33(3): 1551-9.
[75]
Meng W, Wang PS, Liu J, et al. Adenovirus-mediated sirna targeting nob1 inhibits tumor growth and enhances radiosensitivity of human papillary thyroid carcinoma in vitro and in vivo. Oncol Rep 2014; 32(6): 2411-20.
[76]
Liu H, Guo J, Chai H, Meng X. Microrna744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting nob1. Mol Med Rep 2019; 19(3): 1903-10.
[77]
Liu Y, Huang H, Yuan B, Zhuang LY, Luo TP, Zhang Q. Lentivirus-mediated knockdown of nob1 suppresses the proliferation of colon cancer cells. Z Gastroenterol 2014; 52(5): 429-35.
[78]
Huang W-Y, Chen D-H, Ning L, Wang L-W. Sirna mediated silencing of nin1/rpn12 binding protein 1 homolog inhibits proliferation and growth of breast cancer cells. Asian Pacific Journal of Cancer Prevention 2012; 13(5): 1823-7.
[79]
Li XY, Luo QF, Li J, et al. Clinical significance of nob1 expression in breast infiltrating ductal carcinoma. International journal of clinical and experimental pathology 2013; 6(10): 2137-44.
[80]
Ji S, Zhang B, Kong Y, Ma F, Hua Y. Mir-326 inhibits gastric cancer cell growth through downregulating nob1. Oncol Res 2017; 25(6): 853-61.
[81]
Qi H, Wang Y. Nob1 gene as a potential biomarker in clinical outcomes and prognosis of patients with gastric cancer. Clin Lab 2018; 64(9): 1469-75.
[82]
Lu Z, Guo Q, Shi A, Xie F, Lu Q. Downregulation of nin/rpn12 binding protein inhibit the growth of human hepatocellular carcinoma cells. Mol Biol Rep 2012; 39(1): 501-7.
Article Metrics
63
2